Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd in Advanced or Metastatic HER2-Overexpressing NSCLC
NCT07662473Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07662473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662473.